HRP920632B1 - Oral composition for the treatment of inflammatory bowel deseases - Google Patents

Oral composition for the treatment of inflammatory bowel deseases

Info

Publication number
HRP920632B1
HRP920632B1 HRP-2150/90A HRP920632A HRP920632B1 HR P920632 B1 HRP920632 B1 HR P920632B1 HR P920632 A HRP920632 A HR P920632A HR P920632 B1 HRP920632 B1 HR P920632B1
Authority
HR
Croatia
Prior art keywords
treatment
deseases
inflammatory bowel
oral composition
crohn
Prior art date
Application number
HRP-2150/90A
Other languages
English (en)
Inventor
Jan Ulmius
Original Assignee
Jan Ulmius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP920632(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jan Ulmius filed Critical Jan Ulmius
Publication of HRP920632A2 publication Critical patent/HRP920632A2/xx
Publication of HRP920632B1 publication Critical patent/HRP920632B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP-2150/90A 1989-11-22 1992-09-30 Oral composition for the treatment of inflammatory bowel deseases HRP920632B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903914A SE8903914D0 (sv) 1989-11-22 1989-11-22 Oral composition for the treatment of inflammatory bowel diseases
YU215090A YU48583B (sh) 1989-11-22 1990-11-13 Postupak za pripremanje formulacije u obliku pilule za oralno davanje

Publications (2)

Publication Number Publication Date
HRP920632A2 HRP920632A2 (en) 1995-04-30
HRP920632B1 true HRP920632B1 (en) 1999-10-31

Family

ID=20377544

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP-2150/90A HRP920632B1 (en) 1989-11-22 1992-09-30 Oral composition for the treatment of inflammatory bowel deseases

Country Status (36)

Country Link
US (1) US6423340B1 (lv)
EP (1) EP0502092B1 (lv)
JP (1) JP3145111B2 (lv)
KR (1) KR0179042B1 (lv)
AT (1) ATE125445T1 (lv)
AU (1) AU643021B2 (lv)
CA (1) CA2071518C (lv)
DE (1) DE69021214T2 (lv)
DK (1) DK0502092T3 (lv)
EG (1) EG19642A (lv)
ES (1) ES2074698T3 (lv)
FI (2) FI104949B (lv)
GR (1) GR3017691T3 (lv)
HK (1) HK51897A (lv)
HR (1) HRP920632B1 (lv)
HU (2) HU216836B (lv)
IE (1) IE74854B1 (lv)
IL (1) IL96415A (lv)
IS (1) IS1858B (lv)
LT (1) LT3696B (lv)
LV (1) LV10183B (lv)
MY (1) MY104535A (lv)
NO (1) NO304010B1 (lv)
NZ (1) NZ235807A (lv)
PL (1) PL166506B1 (lv)
PT (1) PT95946A (lv)
RU (1) RU2134104C1 (lv)
SA (1) SA90110123B1 (lv)
SE (1) SE8903914D0 (lv)
SG (1) SG54210A1 (lv)
SI (1) SI9012150A (lv)
TW (1) TW250435B (lv)
UA (1) UA37196C2 (lv)
WO (1) WO1991007172A1 (lv)
YU (1) YU48583B (lv)
ZA (1) ZA908777B (lv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
KR960700266A (ko) * 1993-01-08 1996-01-19 클래스 빌헬름슨 신규 결장- 또는 회장-특이성 스테로이드 유도체(Novel Colon-or lleum-Specific Steroid Derivatives)
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO1998022095A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
SE9902673D0 (sv) * 1999-07-12 1999-07-12 Astra Ab New composition
IL157921A0 (en) * 2001-03-15 2004-03-28 Enteron Pharmaceuticals Inc Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE60323138D1 (de) 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
EP1607087A1 (en) * 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
ATE476185T1 (de) * 2003-09-15 2010-08-15 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
PT1670482E (pt) 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20070243184A1 (en) * 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
EP2143424A4 (en) * 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
WO2010040113A1 (en) * 2008-10-03 2010-04-08 Salix Pharmaceuticals, Ltd. Compositions and methods for the treatment of bowel diseases with granulated mesalamine
US8945615B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
PE20140887A1 (es) * 2011-02-04 2014-08-14 Optimer Pharmaceuticals Inc Tratamiento de infecciones bacterianas
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
PT2659881T (pt) 2012-04-30 2018-01-29 Tillotts Pharma Ag Formulação de fármaco de libertação retardada
NZ747731A (en) 2013-10-29 2020-02-28 Tillotts Pharma Ag A delayed release drug formulation
EP3346996A4 (en) * 2015-09-11 2019-04-17 Sun Pharmaceutical Industries Limited ORAL PHARMACEUTICAL PHARMACEUTICAL FORM OF BUDESONID
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
RU2750937C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3413877B1 (en) * 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996356A (en) 1969-07-02 1976-12-07 Hoffmann-La Roche Inc. Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (lv) 1972-05-19 1975-08-18 Bofors Ab
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv) 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8306370D0 (sv) 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
DE3536267A1 (de) 1985-10-11 1987-04-16 Bayer Ag Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv) 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE10307386A1 (de) 2003-02-21 2004-09-09 Dieter Wildfang Gmbh Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

Also Published As

Publication number Publication date
IE74854B1 (en) 1997-08-13
WO1991007172A1 (en) 1991-05-30
RU2134104C1 (ru) 1999-08-10
LV10183B (en) 1995-08-20
ZA908777B (en) 1991-07-31
PL287844A1 (en) 1991-12-02
HU9201700D0 (en) 1992-08-28
JPH05501705A (ja) 1993-04-02
DE69021214D1 (de) 1995-08-31
FI19991893A (fi) 1999-09-06
HUT60630A (en) 1992-10-28
NO304010B1 (no) 1998-10-12
FI922325A (fi) 1992-05-21
LTIP1751A (en) 1995-07-25
KR920703025A (ko) 1992-12-17
IS3644A7 (is) 1991-05-23
HU216836B (hu) 1999-09-28
LV10183A (lv) 1994-10-20
EP0502092B1 (en) 1995-07-26
NO922004D0 (no) 1992-05-21
FI922325A0 (fi) 1992-05-21
MY104535A (en) 1994-04-30
IL96415A0 (en) 1991-08-16
IS1858B (is) 2003-03-27
LT3696B (en) 1996-02-26
IE904170A1 (en) 1991-05-22
SI9012150A (sl) 1998-08-31
GR3017691T3 (en) 1996-01-31
KR0179042B1 (ko) 1999-03-20
HRP920632A2 (en) 1995-04-30
CA2071518C (en) 2002-11-12
FI104949B (fi) 2000-05-15
US6423340B1 (en) 2002-07-23
NZ235807A (en) 1993-02-25
ATE125445T1 (de) 1995-08-15
TW250435B (lv) 1995-07-01
DE69021214T2 (de) 1996-01-04
PT95946A (pt) 1991-09-13
CA2071518A1 (en) 1991-05-23
EG19642A (en) 1995-08-30
IL96415A (en) 1995-11-27
JP3145111B2 (ja) 2001-03-12
PL166506B1 (pl) 1995-05-31
SA90110123B1 (ar) 1999-06-06
YU215090A (sr) 1996-01-09
SE8903914D0 (sv) 1989-11-22
NO922004L (no) 1992-05-21
SG54210A1 (en) 1998-11-16
AU7786491A (en) 1991-06-13
ES2074698T3 (es) 1995-09-16
UA37196C2 (uk) 2001-05-15
AU643021B2 (en) 1993-11-04
YU48583B (sh) 1998-12-23
HK51897A (en) 1997-05-02
EP0502092A1 (en) 1992-09-09
DK0502092T3 (da) 1995-12-27

Similar Documents

Publication Publication Date Title
HRP920632B1 (en) Oral composition for the treatment of inflammatory bowel deseases
ZA899176B (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma and pharmaceutical compositions useful in such treatment
IL107518A0 (en) Therapeutic and diagnostic compositions comprising purified surface modifiers to prevent particle aggregation during sterilization
GEP20012448B (en) Tissue Plasminogen Activators (Improved Variants)
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
FR2784897B1 (fr) Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
AU5201793A (en) Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
AU2742395A (en) Therapeutic or dietetic composition in the form of medicinal gel for the administration to pets
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
GB9401745D0 (en) Improvements in and relating to the administration of medicaments or therapeutic substances
GR3030600T3 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.
ZA938959B (en) Alpha, omega-diaralaikane derivatives,their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20091026

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20101114